Last reviewed · How we verify

NCT04815395

Differential Effects of Oral and Intranasal Oxytocin on Attention Control

Completed NA Last updated 25 March 2021
What this trial tests

NA trial testing Oxytocin in Healthy in 151 participants. Completed in 1 January 2021.

Timeline
19 December 2017
Primary endpoint
1 January 2021
1 January 2021

Quick facts

Lead sponsorUniversity of Electronic Science and Technology of China
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposebasic science
Enrollment151
Start date19 December 2017
Primary completion1 January 2021
Estimated completion1 January 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

University of Electronic Science and Technology of China

Who can join

Adults 18 to 30, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of the present study is to investigate whether oxytocin (24IU) via different routes have divergent effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Oral Administration of Oxytocin, Like Intranasal Administration, Decreases Top-Down Social Attention.
    Zhuang Q, Zheng X, Yao S, Zhao W, et al · · 2022 · cited 17× · PMID 36053298 · DOI 10.1093/ijnp/pyac059

Verify or expand the search:

Other trials of Oxytocin

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other University of Electronic Science and Technology of China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04815395.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing